The mediational effects of FDG hypometabolism on the association between cerebrospinal fluid biomarkers and neurocognitive function

NeuroImage

Volumn 105, Issue , 2015, Pages 357-368

  Dowling, N Maritza ^a,b   Johnson, Sterling C ^b,c   Gleason, Carey E ^b,c   Jagust, William J ^d,e  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

Author keywords

Alzheimer's disease; Beta amyloid; CSF biomarkers; FDG PET; Longitudinal mediation; Parallel process latent growth; Structural equation modeling; Tau

Indexed keywords

BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

AGED; ALZHEIMER DISEASE; BRAIN; CEREBROSPINAL FLUID; HUMAN; MALE; METABOLISM; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BIOMARKERS; BRAIN; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 84914170392     PISSN: 10538119     EISSN: 10959572     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2014.10.050     Document Type: Article

References (81)

1. Arlt S., Brassen S., Jahn H., Wilke F., Eichenlaub M., Apostolova I., Buchert R. Association between FDG uptake, CSF biomarkers and cognitive performance in patients with probable Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging 2009, 36:1090-1100.
2. Bentler P.M., Bonett D.G. Significance tests and goodness of fit in the analysis of covariance structures. Psychological Bulletin 1980, 88:588-606.
3. Browne M.W., Cudeck R. Alternative Ways of Assessing Model Fit. Testing Structural Equation Models 1993, 136-162. Sage, Newbury Park, CA. K. Bollen, J. Long (Eds.).
4. Cheong J., MacKinnon D.P., Khoo S.T. Investigation of meditational process using parallel process latent growth curve modeling. Structural Equation Modeling 2003, 10:238-262.
5. Chien D.T., Szardenings A.K., Bahri S., Walsh J.C., Mu F., Xia C., Kolb H.C. Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. Journal of Alzheimer's Disease 2014, 38:171-184.
6. Choo I.H., Ni R., Schöll M., Wall A., Almkvist O., Nordberg A. Combination of 18F-FDG PET and cerebrospinal fluid biomarkers as a better predictor of the progression to Alzheimer's disease in mild cognitive impairment patients. Journal of Alzheimer's Disease 2013, 33:929-939.
7. Craig-Schapiro R., Perrin R.J., Roe C.M., Xiong C., Carter D., Cairns N.J., Holtzman D.M. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biological Psychiatry 2010, 68:903-912.
8. De Leon M.J., Convit A., Wolf O.T., Tarshish C.Y., DeSanti S., Rusinek H., Fowler J. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-d-glucose/positron-emission tomography (FDG/PET). Proceedings of the National Academy of Sciences of the United States of America 2001, 98:10966-10971.
9. de Leon M.J., DeSanti S., Zinkowski R., Mehta P.D., Pratico D., Segal S., Davies P. Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiology of Aging 2006, 27:394-401.
10. Drzezga A., Becker A., Van Dijk K., Sreenivasan A., Talukdar T., Sullivan C., Putcha D. Neuronal dysfunction and disconnection of cortical hubs in non-demented subjects with elevated amyloid burden. Brain 2011, 134:1635-1646.
11. Efron B., Tibshirani R.J. An introduction to the bootstrap 1993, Chapman & Hall, New York, NY.
12. Fagan A.M., Roe C.M., Xiong C., Mintun M.A., Morris J.C., Holtzman D.M. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Archives of Neurology 2007, 64:343-349.
13. Fellgiebel A., Siessmeier T., Scheurich A., Winterer G., Bartenstein P., Schmidt L.G., Müller M.J. Association of elevated phospho-tau levels with Alzheimer-typical 18F-fluoro-2-deoxy-d-glucose positron emission tomography findings in patients with mild cognitive impairment. Biological Psychiatry 2004, 56:279-283.
14. Fellgiebel A., Scheurich A., Bartenstein P., Muller M.J. FDG-PET and CSF phospho-tau for prediction of cognitive decline in mild cognitive impairment. Psychiatry Research 2007, 155:167-171.
15. Folstein M.F., Folstein S.E., McHugh P.R. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 1975, 12:189-198.
16. Fonteijn H.M., Modat M., Clarkson M.J., Barnes J., Lehmann M., Hobbs N.Z., Scahill R.I., Tabrizi S.J., Ourselin S., Fox N.C., Alexander D.C. An event-based model for disease progression and its application in familial Alzheimer's disease and Huntington's disease. Neuroimage 2012, 60:1880-1889.
17. Hansson O., Zetterberg H., Buchhave P., Londos E., Blennow K., Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurology 2006, 5:228-234.
18. Herholz K. PET studies in dementia. Annals of Nuclear Medicine 2003, 17:79-89.
19. Horn J.L., McArdle J.J. A practical and theoretical to measurement invariance in aging research. Experimental Aging Research 1992, 18:117-144.
20. Hu L.T., Bentler P. Evaluating model fit. Structural Equation Modeling. Concepts, Issues, and Applications 1995, 76-99. Sage, London. R.H. Hoyle (Ed.).
21. Hunt A., Schonknecht P., Henze M., Toro P., Haberkorn U., Schroder J. CSF tau protein and FDG PET in patients with aging-associated cognitive decline and Alzheimer's disease. Neuropsychiatric Disease and Treatment 2006, 2:207-212.
22. Imai K., Keele L., Tingley D. A general approach to causal mediation analysis. Psychological Methods 2010, 15:309-334.
23. Jack C.R., Knopman D.S., Jagust W.J., Petersen R.C., Weiner M.W., Aisen P.S., Trojanowski J.Q. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurology 2013, 12:207-216.
24. Jagust W.J., Gitcho A., Sun F., Kuczynski B., Mungas D., Haan M. Brain imaging evidence of preclinical Alzheimer's disease in normal aging. Annals of Neurology 2006, 59:673-681.
25. Jagust W.J., Landau S.M., Shaw L.M., Trojanowski J.Q., Koeppe R.A., Reiman E.M., Mathis C.A. Relationships between biomarkers in aging and dementia. Neurology 2009, 73:1193-1199.
26. Jagust W.J., Bandy D., Chen K., Foster N.L., Landau S.M., Mathis C.A., Koeppe R.A. The Alzheimer's disease neuroimaging initiative positron emission tomography core. Alzheimer's & Dementia: the journal of the Alzheimer's Association 2010, 6:221-229.
27. Jo B. Causal inference in randomized experiments with mediational processes. Psychological Methods 2008, 13:314-336.
28. Johnson S.C., Christian B.T., Okonkwo O.C., Oh J.M., Harding S., Xu G., Sager M.A. Amyloid burden and neural function in people at risk for Alzheimer's disease. Neurobiology of Aging 2014, 35:576-584.
29. Joshi A., Koeppe R.A., Fessler J.A. Reducing between scanner differences in multicenter PET studies. NeuroImage 2009, 46:154-159.
30. Kilian L. Small-sample Confidence Intervals for Impulse Response Functions. Review of Economics and Statistics 1998, 80:218-230.
31. Landau S.M., Harvey D., Madison C.M., Reiman E.M., Foster N.L., Aisen P.S., Jagust W.J. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 2010, 75:230-238.
32. Landau S.M., Harvey D., Madison C.M., Koeppe R.A., Reiman E.M., Foster N.L., Jagust W.J. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiology of Aging 2011, 32:1207-1218.
33. Landau S.M., Mintun M.A., Joshi A.D., Koeppe R.A., Petersen R.C., Aisen P.S., Jagust W.J. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Annals of Neurology 2012, 72:578-586.
34. Li G., Sokal I., Quinn J.F., Leverenz J.B., Brodey M., Schellenberg G.D., Kaye J.A., Montine T.J. CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology 2007, 69:631-639.
35. Lo R.Y., Hubbard A.E., Shaw L.M., Trojanowski J.Q., Petersen R.C., Aisen P.S., Jagust W.J. Longitudinal change of biomarkers in cognitive decline. Archives of Neurology 2011, 68:1257-1266.
36. MacKinnon D.P., Lockwood C.M., Williams J. Confidence limits for the indirect effect: distribution of the product and resampling methods. Multivariate Behavioral Research 2004, 39:99-128.
37. McArdle J.J., Ferrer-Caja E., Hamagami F., Woodcock R.W. Comparative longitudinal structural analyses of growth and decline of multiple intellectual abilities over the lifespan. Developmental Psychology 2002, 38:115-142.
38. Meredith W. Measurement invariance, factor analysis, and factorial invariance. Psychometrika 1993, 58:525-542.
39. Meredith W., Tisak J. Latent curve analysis. Psychometrika 1990, 55:107-122.
40. Mohs K., Rosen W., Davis K. The Alzheimer's disease assessment scale: an instrument for assessing treatment efficacy. Psychopharmacology Bulletin 1983, 19:448-450.
41. Mosconi L., De Santi S., Brys M., Tsui W.H., Pirraglia E., Glodzik-Sobanska L., de Leon M.J. Hypometabolism and altered CSF markers in normal ApoE E4 carriers with subjective memory complaints. Biological Psychiatry 2008, 63:609-618.
42. Mosconi L., Mistur R., Switalski R., Tsui W.H., Glodzik L., Brys M., de Leon M.J. Longitudinal changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging 2009, 36:811-822.
43. Mosconi L., Berti V., Glodzik L., Pupi A., De Santi S., de Leon M.J. Pre-clinical detection of Alzheimer's disease using FDG-PET, with or without amyloid imaging. Journal of Alzheimer's Disease 2010, 20:843-854.
44. Mosconi L., Rinne J.O., Tsui W.H., Murray J., Li Y., Glodzik L., de Leon M.J. Amyloid and metabolic positron emission tomography imaging of cognitively normal adults with Alzheimer's parents. Neurobiology Aging 2013, 34:22-34.
45. Muthén B., Asparouhov T. Causal effects in mediation modeling: an introduction with applications to latent variables. Structural Equation Modeling 2014, (forthcoming). 10.1080/10705511.2014.935843.
46. Muthén B.O., Curran P.J. General longitudinal modeling of individual differences in experimental designs: a latent variable framework for analysis and power estimation. Psychological Methods 1997, 2:371-402.
47. Muthén L.K., Muthén B.O. Mplus User's Guide 2013, Muthén & Muthén, Los Angeles, CA. Seventh edition.
48. Niedowicz D.M., Beckett T.L., Matveev S., Weidner A.M., Baig I., Kryscio R.J., Murphy M.P. Pittsburgh compound B and the postmortem diagnosis of Alzheimer's disease. Annals of Neurology 2012, 72:564-570.
49. Oh H., Habeck C., Madison C., Jagust W. Covarying alterations in Aβ deposition, glucose metabolism, and gray matter volume in cognitively normal elderly. Human Brain Mapping 2014, 35:297-308.
50. Okamura N., Arai H., Higuchi M., Tashiro M., Matsui T., Itoh M., Sasaki H. Cerebrospinal fluid levels of amyloid beta-peptide 1-42, but not tau have positive correlation with brain glucose metabolism in humans. Neuroscience Letters 1999, 273:203-207.
51. Okamura N., Furumoto S., Fodero-Tavoletti M.T., Mulligan R.S., Harada R., Yates P., Villemagne V.L. Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET. Brain 2014, 10.1093/brain/awu064.
52. Perez-Nievas B.G., Stein T.D., Tai H.C., Dols-Icardo O., Scotton T.C., Barroeta-Espar I., Gómez-Isla T. Dissecting phenotypic traits linked to human resilience to Alzheimer's pathology. Brain 2013, 136:2510-2526.
53. Petrie E.C., Cross D.J., Galasko D., Schellenberg G.D., Raskind M.A., Peskind E.R., Minoshima S. Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings. Archives of Neurology 2009, 66:632-637.
54. Preacher K.J., Hayes A.F. Asymptotic and resampling strategies for assessing and comparing indirect effects in multiple mediator models. Behavior Research Methods 2008, 40:879-891.
55. Reiman E.M., Caselli R.J., Yun L.S., Chen K., Bandy D., Minoshima S., Osborne D. Preclinical evidence of Alzheimer's disease in persons homozygous for the e4 allele for apolipoprotein E. The New England Journal of Medicine 1996, 334:752-758.
56. Reiman E.M., Caselli R.J., Chen K., Alexander G.E., Bandy D., Frost J. Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: a foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proceedings of the National Academy of Science of the United States of America 2001, 98:3334-3339.
57. Reiman E.M., Quiroz Y.T., Fleisher A.S., Chen K., Velez-Pardo C., Jimenez-Del-Rio M., Lopera F. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurology 2012, 11:1048-1056.
58. Roe C.M., Fagan A.M., Grant E.A., Hassenstab J., Moulder K.L., Maue D., Morris J.C. Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5years later. Neurology 2013, 80:1784-1791.
59. Rosen W., Mohs R., Davis K. A new rating scale for Alzheimer's disease. The American Journal of Psychiatry 1984, 141:1356-1364.
60. Rovine M.J., Molenaar P.C.M. A structural equations modeling approach to the general linear mixed model. New methods for the analysis of change. Decade of behavior. 2001, 67-98. American Psychological Association, Washington, DC, US. L.M. Collins, A.G. Sayer (Eds.).
61. Salthouse T.A. Neuroanatomical substrates of age-related cognitive decline. Psychological Bulletin 2011, 137:753-784.
62. Schaie K.W., Maitland S.B., Willis S.L., Intrieri R.C. Longitudinal invariance of adult psychometric ability factor structures across 7years. Psychology and Aging 1998, 12:8-20.
63. Schermelleh-Engel K., Moosbrugger H., Müller H. Evaluating the fit of structural equation models: Test of significance and descriptive goodness-of-fit measures. Methods of Psychological Research 2003, 8:23-74.
64. Selig J.P., Preacher K.J. Mediation models for longitudinal data in developmental research. Research in Human Development 2009, 6:144-164.
65. Shaw L.M. PENN biomarker core of the Alzheimer's disease neuroimaging initiative. Neuro Signals 2008, 16:19-23.
66. Shaw L.M., Vanderstichele H., Knapik-Czajka M., Clark C.M., Aisen P.S., Petersen R.C., Trojanowski J.Q. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Annals of Neorology 2009, 65:403-413.
67. Singer J.D., Willett J.B. Applied longitudinal data analysis: Modeling change and event occurrence 2003, Oxford University press.
68. Sluimer J.D., Bouwman F.H., Vrenken H., Blankenstein M.A., Barkhof F., van der Flier W.M., Scheltens P. Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study. Neurobiology of Aging 2010, 31:758-764.
69. Small G.W., Ercoli L.M., Silverman D.H., Huang S.C., Komo S., Bookheimer S.Y., Phelps M.E. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:6037-6042.
70. Snider B.J., Fagan A.M., Roe C., Shah A.R., Grant E.A., Xiong C., Holtzman D.M. Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Archives of Neurology 2009, 66:638-645.
71. Tombaugh T.N., McIntyre N.J. The mini-mental state examination: a comprehensive review. Journal of the American Geriatric Society 1992, 40:922-935.
72. Tucker L.R., Lewis C. A reliability coefficient for maximum likelihood factor analysis. Psychometrika 1973, 38:1-10.
73. Tucker-Drob E.M., Salthouse T.A. Individual differences in cognitive aging. The Wiley-Blackwell Handbook of Individual Differences 2011, 242-267. Wiley-Blackwell, London. First Edition. T. Chamorro-Premuzic, S. von Stumm, A. Furnham (Eds.).
74. Villemagne V.L., Burnham S., Bourgeat P., Brown B., Ellis K.A., Salvado O., Masters C.L. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurology 2013, 12:357-367.
75. Wang C.P., Brown C.H., Bandeen-Roche K. Residual diagnostics for growth mixture models: Examining the impact of a preventive intervention on multiple trajectories of aggressive behaviour. Journal of the American Statistical Association 2005, 100:1054-1076.
76. Wouters H., van Gool W.A., Schmand B., Zwinderman A.H., Lindeboom R. Three sides of the same coin: measuring global cognitive impairment with the MMSE, ADAS-Cog and CAMCOG. International Journal of Geriatric Psychiatry 2010, 25:770-779.
77. Wu W., West S.G., Taylor A.B. Evaluating model fit for growth curve models: integration of fit indices from SEM and MLM frameworks. Psychological Methods 2009, 14:183-201.
78. Xia C.-F., Arteaga J., Chen G., Gangadharmath U., Gomez L.F., Kasi D., Kolb H.C. [18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. Alzheimer's & Dementia 2013, 9:666-676.
79. Young A.L., Oxtoby N.P., Daga P., Cash D.M., Fox N.C., Ourselin S., Alexander D.C. A data-driven model of biomarker changes in sporadic Alzheimer's disease. Brain 2014, 137:2564-2577.
80. Zhang D., Shen D. Multi-modal multi-task learning for joint prediction of multiple regression and classification variables in Alzheimer's disease. Neuroimage 2011, 59:895-907.
81. Zhang D., Shen D. Predicting future clinical changes of MCI patients using longitudinal and multimodal biomarkers. PLoS ONE 2012, 7.